Give the Heart a Ketone? It May be Beneficial

February 23, 2021

Heart Ketone: There is growing evidence that ketone bodies may be beneficial to heart disease patients regardless of the method of delivery used to increase ketone delivery to the heart.

A Journal of the American College of Cardiology review paper examines emerging evidence regarding ketone bodies’ effects on the heart and the potential for ketone therapy as a cardiovascular intervention in heart disease patients.

In recent years ketone bodies entered the popular lexicon through the “keto diet,” which consists of a very low carbohydrate and high-fat diet that endeavors to force the body into ketosis. This is a metabolic state with increased ketone bodies circulating in the body as a result of less glucose, or sugar, being in the bloodstream to provide fuel, causing the body to shift to metabolize fat as energy. Recent research has shown that a keto diet may contribute to increased risk for heart disease if the foods consumed do not include heart-healthy fats.

The review discusses the therapeutic advantages of increasing circulating ketone levels through multiple mechanisms, including the keto diet. The researchers discuss both the potential merits and concerns related to the keto diet in relation to each mechanism for increasing ketone levels in the body, providing novel therapeutic avenues to increase ketosis without the concerning impacts of the keto diet.

“We found that data from experimental and human studies suggest ketone bodies exert protective effects on patients with heart disease. As heart disease remains the leading killer worldwide, determining new ways to offer cardiac protection is vital to this patient population,” said B. Daan Westenbrink, MD, Ph.D., a cardiologist and translational scientist at University Medical Center Groningen in the Netherlands and senior author on the paper. “While the keto diet has become increasingly popular, there are concerns about untoward effects on the heart. However, administration of ketones may be an alternative to a keto diet as a means of elevating ketone bodies for their protective effects.”

Ketone bodies are produced by the liver, particularly in response to prolonged fasting, insulin deprivation, and extreme exercise. Ketones provide additional energy to multiple organs, and under extreme conditions, ketone bodies may account for approximately 5-20% of total energy expenditure by the body.

Under normal conditions, a healthy heart consumes little glucose as an energy source. However, in the early stages of structural heart disease, there is a switch from fatty acids to glucose utilization. This metabolic reprogramming leads to heart muscle energy starvation, contributing to the development of heart failure. According to the researchers, a failing heart seems to reprogram its metabolism to increased reliance on ketone bodies as a fuel source.

According to the researchers, ketones may also have positive effects on common cardiovascular risk factors, including blood pressure, body weight, blood glucose or blood sugar, and cholesterol, though research is ongoing. Research has also shown ketone bodies may provide additional cardiovascular benefits impacting endothelial function, inflammation, cardiac remodeling, and mitochondrial function.

These benefits could be achieved through the keto diet, but long-term compliance to the diet is low, often due to gastrointestinal distress. There are alternatives to the keto diet or ingesting ketone precursors to achieve ketosis, which includes ingesting ketone salts or ketone esters.

“With numerous pathways to achieve ketosis, ketone bodies have potential clinical implications that require further study,” Westenbrink said. “Further exploration of therapeutic approaches to harness the beneficial effects of ketosis are necessary. I believe in the coming years we will have a much better grasp on whether ketone bodies can be optimized and used in the treatment and prevention of heart disease.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”